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perturbations in tRNA architecture
LUC BONNEFOND, CATHERINE FLORENTZ, RICHARD GIEGE´, and JOE¨LLE RUDINGER-THIRION
Architecture et Re´activite´ de l’ARN, Universite´ Louis Pasteur de Strasbourg, CNRS, 67084 Strasbourg, France
ABSTRACT
A growing number of human pathologies are ascribed to mutations in mitochondrial tRNA genes. Here, we report biochemical
investigations on three mt-tRNATyr molecules with point substitutions associated with diseases. The mutations occur in the
atypical T- and D-loops at positions homologous to those involved in the tertiary interaction network of canonical tRNAs. They
do not correspond to tyrosine identity positions and likely do not contact the mitochondrial tyrosyl-tRNA synthetase during the
aminoacylation process. The impact of these substitutions on mt-tRNATyr tyrosylation and structure was investigated using the
corresponding tRNA transcripts. In vitro tyrosylation efficiency is decreased 600-fold for mutant A22G (mitochondrial gene
mutation T5874C), 40-fold for G15A (C5877T), and is without significant effect on U54C (A5843G). Comparative solution
probings with lead and nucleases on mutant and wild-type tRNATyr molecules reveal a greater sensitivity to single-strand
specific probes for mutants G15A and A22G. For both transcripts, the mutation triggers a structural destabilization in the
D-loop that propagates toward the anticodon arm and thus hinders efficient tyrosylation. Further probing analysis combined
with phylogenetic data support the participation of G15 and A22 in the tertiary network of human mt-tRNATyr via
nonclassical Watson–Crick G15–C48 and G13–A22 pairings. In contrast, the pathogenic effect of the tyrosylable mutant U54C,
where structure is only marginally affected, has to be sought at another level of the tRNATyr life cycle.
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INTRODUCTION
A large number of mutations in human mitochondrial
transfer RNA (mt-tRNA) genes have been correlated with
degenerative disorders concerning brain, heart, muscles,
eyes, kidneys, and endocrine glands (for review, see Wallace
1999; Chinnery and Turnbull 2000; Jacobs and Holt 2000).
Since tRNAs are key molecules interacting with a variety of
partners during the translational process, it is understand-
able that mutations can disturb various mitochondrial func-
tions. Following this rationale, biochemical studies indeed
revealed that pathogenic mutations can affect tRNAs at
various steps including its structure, 39-end maturation,
post-transcriptional modifications, aminoacylation, com-
plex formation with translation factors, association with
ribosomes and decoding process (for review, see Florentz
et al. 2003; Wittenhagen and Kelley 2003; Levinger et al. 2004;
Taylor and Turnbull 2005). Presently, more than 130 mu-
tations were described, distributed among all the 22 human
mt-tRNA species encoded by the mitochondrial genome
(see http://www.mitomap.org) (Brandon et al. 2005).
This report relates to the human mt-tRNATyr gene in
which three single substitutions lead to a set of diseases.
The pathogenic mutations correspond to the single sub-
stitutions C5877T, T5874C, and A5843G in the mitochon-
drial genome that lead to familial chronic progressive
external ophtalmoplegia (Sahashi et al. 2001), exercise
intolerance associated with complex III deficiency (Pulkes
et al. 2000), and mitochondrial cytopathy (Scaglia et al.
2003), respectively. The choice of studying human mt-
tRNATyr was dictated by several considerations. First, the
recently solved crystal structure of the mt-TyrRS (Bonnefond
et al. 2007a,b) makes it possible to present a model for the
interaction of human mitochondrial tRNATyr with mt-
TyrRS, which help to understand the effects triggered by
the mutations. Second, substitutions G15A, A22G, and
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U54C in human mt-tRNATyr occur in
loops (Fig. 1A) in contrast to the
majority (66%) of point mutations that
are found in stem regions of mt-tRNAs
(Florentz and Sissler 2001; McFarland
et al. 2004). Third, up to date, basic
research was essentially concentrated on
four human mt-tRNAs genes that are
‘‘hotspots’’ for mutations (coding for
tRNALeu(UUR), tRNALys, tRNAIle, and
tRNASer(UCN)) with no biochemical
investigations on tRNATyr. Finally, most
studied mt-tRNAs belong to the
‘‘light’’1 tRNA family containing few G
residues (e.g., human mt-tRNALeu(UUR),
tRNALys, tRNAIle) and therefore are in-
trinsically fragile (Florentz et al. 2003),
whereas tRNATyr is a ‘‘heavy’’ tRNA
anticipated to be more structured.
In this study, we investigate the
impact of the three mt-tRNATyr patho-
genic substitutions using in vitro tyro-
sylation assays combined with solution
probing experiments. We show that
both D-loop mutations perturb the
tRNATyr tertiary folding and thereafter
hinder efficient recognition by the
homologous TyrRS. On the contrary,
the T-loop mutation alters neither the
global tRNA structure nor its tyrosyla-
tion properties. Altogether, the results
presented allow us to propose a struc-
tural relationship between the D-loop
and variable region in mt-tRNATyr as
well as two tertiary interactions.
RESULTS AND DISCUSSION
Human mt-tRNATyr
Comparison of the 150 mammalian mt-tRNATyr sequences
available (http://mamit-tRNA.u-strasbg.fr; Pu¨tz et al. 2007)
reveals 80% of conserved residues, especially located in
stems and anticodon loop (Fig. 1A). Differences occur
mainly in T- and D-loops that vary in sequence and size
(D-loops from three to six nucleotides [nt]; T-loops from
three to eight nt). Further, mammalian mt-tRNATyr species
do not contain a subset of nucleotides known to be
involved in the tertiary interaction network of canonical
tRNAs (Giege´ et al. 1993). Thus, in the particular case of
human mt-tRNATyr, representative of mammalian tyrosine
specific tRNAs (Fig. 1A), D-loop lacks the conserved G18–
G19 dinucleotide usually involved in two tertiary interac-
tions with T-loop residues (Helm et al. 2000) but presents
G13 and A22 residues, characteristic of class II tRNA
species2 (Giege´ et al. 1993). Both nucleotides are prone to
pair via a trans-Hoogsteen/sugar edge interaction (Leontis
et al. 2002) as seen in the crystal structure of Thermus
thermophilus tRNATyr (Yaremchuk et al. 2002). The T-loop
consists of five nt instead of seven nt in classical tRNAs, and
lacks both conserved C56 and A58 residues involved in
long-range interactions (with G18 and U54, respectively).
FIGURE 1. Location of pathology-related mutations in human mitochondrial tRNATyr. (A)
Model of secondary structure of human mt-tRNATyr, a tRNA belonging to the ‘‘heavy’’ mt-
tRNA family with 26% of G residues (Helm et al. 2000). Positions of pathogenic point
substitutions, as found in mitochondrial DNA, are circled and the corresponding mutations in
the gene with associated clinical effects are explicitly given. Dashed lines indicate putative
tertiary interactions as proposed by Helm et al. (2000). Sequence data and numbering are
according to Anderson et al. (1981) and Sprinzl and Vassilenko (2005), respectively. Residues
in bold are those highly conserved (> 90%) in 150 mammalian mt-tRNATyr species (Pu¨tz et al.
2007). Notice that gene mutation A5843G, previously annotated C55 in mt-tRNATyr, is
considered in this work as C54 according to the mt-tRNA database numbering from Pu¨tz et al.
(2007). A fourth pathogenic mutant was not considered in this work since it concerns a
nucleotide deletion in the acceptor stem (Raffelsberger et al. 2001). (B) Interaction model of
human mt-TyrRS with tRNA. The mt-TyrRS crystal structure is from Bonnefond et al.
(2007b); the homodimeric organization is emphasized by darkening one monomer. Docking
of tRNA across both TyrRS subunits was achieved taking into account sequence and
crystallographic knowledge of tyrosine systems (Bedouelle 2005). Gray dots show the tyrosine
identity elements as determined by Bonnefond et al. (2005b), whereas black dots indicate
location of the three pathogenic mutations on a tRNA backbone.
1tRNA genes are distributed either on the heavy (G-rich) or light mt-
DNA strand (C-rich). Transcription of the heavy DNA chain leads to 14
‘‘light’’ mt-tRNAs and transcription of the light DNA chain leads to eight
‘‘heavy’’ mt-tRNAs (Anderson et al. 1981).
2Class II tRNAs (Leu, Ser, Sec, and bacterial Tyr) possess a large variable
region (over 10 nt) in opposition to class I tRNAs with a small variable
region (up to five nt).
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Consequently, the 3D folding of this tRNA cannot involve
classical D/T-loop interactions, and will likely be achieved
via an alternative network, not yet identified, that may still
include other classical tertiary interactions (see Fig. 1A; for
review, see Helm et al. 2000). The pathogenic mutations
G15A, A22G, and U54C in the human mt-tRNATyr gene are
located at positions usually involved in the classical tertiary
interaction network. Notice further that the three residues
are remote from the synthetase and excluded from a direct
interaction in the interaction model proposed in Figure 1B.
This model is based on the recently solved crystal structure
of mt-TyrRS (Bonnefond et al. 2007b) combined with
knowledge on tRNATyr/TyrRS complexes showing a cross-
subunit binding of the tRNA (Bedouelle 2005). Also, the
location of all three residues in the tRNA differs from that
of the tyrosine identity nucleotides. These latter, determin-
ing tyrosylation specificity and interact-
ing with the synthetase, are found at the
two distal ends of the tRNA (Bonnefond
et al. 2005b). Given these facts, it can be
hypothesized that the pathogenic muta-
tions may induce a structural perturba-
tion in mt-tRNATyr, and therefore
indirectly affect the tyrosylation ability
of the mutants.
In this work, wild-type and mutated
molecules were produced by in vitro
transcription. Since transcripts do not
contain the post-transcriptional modifi-
cations known to stabilize tRNA folding
(e.g., Agris 1996) or induce the correct
cloverleaf folding as shown for human
mt-tRNALys (Helm et al. 1998), one can
wonder about the conformation of these
molecules. Therefore, as a prerequisite
to our study, we investigated whether
the folding of the wild-type transcript
was of the anticipated cloverleaf-type.
Probing of wild-type human
mt-tRNATyr structure
A wild-type mt-tRNATyr transcript was
probed with chemical (Pb2+) and enzy-
matic probes (nucleases S1, T1, T2)
known to preferentially cleave single-
stranded regions, as well as with nucle-
ase V1 specific of double-stranded and
structured RNA regions (Giege´ et al.
2001) (Fig. 2). The S1, T1, T2, and lead
cleavage patterns show strong cuts in the
anticodon-, T-, and D-loops, whereas
the acceptor-, D-, T-, and anticodon
arms are cleaved by nuclease V1 and are
mainly insensitive to lead (Fig. 2A),
thereby supporting the existence of the cloverleaf-fold
depicted in Figure 1A. However, some residues within the
tRNA arms (particularly the anticodon arm) are cut by the
single strand-specific nucleases, and conversely, few re-
sidues located in D- and anticodon loops are recognized by
nuclease V1, the probe specific for highly structured
regions. Further, residues belonging to the anticodon arm
are sensitive to Pb2+ cleavage, suggesting an opening of this
region. These apparently contradictory data reflect the exis-
tence of alternate tRNA conformations in equilibrium with
the canonical cloverleaf as previously shown in probing
experiments conducted on other mt-tRNAs (e.g., human
mt-tRNALys) (Helm et al. 1998) and mt-tRNALeu(UUR)
(Sohm et al. 2003). However, the high tyrosylation level
(over 80%, not shown) observed for the wild-type molecule
reflects a large proportion of correctly folded transcripts
FIGURE 2. Probing of wild-type human mt-tRNATyr transcript. (A) Autoradiogram of a 12%
denaturing gel of probing experiments on 59-labeled mt-tRNATyr. Experiments were
conducted at 25°C using Pb2+, RNases T1, T2, and V1 and nuclease S1 as described in
The´obald-Dietrich et al. (2004). Final concentrations of Pb2+ (in mM) are indicated. Control
incubation (lane C) without probes was run in parallel. Lane S1 is a control that checks the
effect of ZnCl2 present in nuclease S1 buffer. Lane L represents an alkaline ladder, and lane
G represents a denaturing RNase T1 ladder (each G residue is numbered). D-loop (D),
anticodon-loop (AC), variable region (v) and T-loop (T) are indicated by black vertical bars.
(B) Summary of the probing experiments displayed on mt-tRNATyr cloverleaf (only the
strongest nuclease cuts and lead protections are taken into account for interpretation).
Nucleotides cut by nucleases S1, T1, and T2 are indicated by triangles. White letters on black
backgrounds emphasize cleavages by RNase V1. Regions resistant to Pb2+ cuts are boxed.
Yellow areas correspond to nucleotides cut by nucleases specific for single-stranded regions.
Blue areas correspond to nucleotides cut by V1 nuclease or insensitive to lead cleavage. Regions
cut by both types of enzymatic probes are in green. Bars at the 39- and 59-ends indicate
noninterpretable regions.
tRNA structure perturbations and pathologies
www.rnajournal.org 643
JOBNAME: RNA 14#4 2008 PAGE: 3 OUTPUT: Saturday March 8 14:52:40 2008
csh/RNA/152278/rna9381
Fig. 2 live 4/C
upon interaction with the synthetase. Notice the presence
in control lanes of some faint hydrolytic cleavages (Fig. 2A)
that become visible at PyA (Py for pyrimidine) positions
when the autoradiogram is overexposed (data not shown).
Altogether, our data indicate that the wild-type human
mt-tRNATyr transcript is intrinsically structured, and folds
preferentially in a cloverleaf despite the absence of post-
transcriptional modifications (Fig. 2B). This interpretation
is in line with the ranking of this molecule among the
‘‘heavy’’ mt-tRNAs with an excess of G-residues (on
average 27%) as opposed to the ‘‘light’’ species (on average
14%) (Florentz et al. 2003), which consequently fold into
less stable structures as, for example, human tRNALys
(Sissler et al. 2004).
Tyrosylation activity of wild-type and mutated human
mt-tRNATyr transcripts
Steady-state parameters for tyrosylation of these tRNA
molecules by native human mt-TyrRS are summarized in
Table 1. Whereas variant U54C behaves similarly to wild-
type mt-tRNATyr, substitutions of G15 by A, and especially
of A22 by G, significantly affect the tyrosylation capacity of
both molecules with losses in catalytic efficiency (kcat/KM)
of 40- and 600-fold, respectively. Kinetic parameters re-
vealed a predominant effect on kcat (KM only being affected
up to sixfold) in accordance with that observed on other
aminoacylation systems (e.g., Kelley et al. 2000; Sissler et al.
2004). Since direct interaction between residues 15, 22, and
54 and the cognate dimeric mt-TyrRS is unlikely (Fig. 1B),
it implies that the reduced aminoacylation efficiency of the
mutants occurs via structural perturbations that are a priori
strongest for A22G, moderate for G15A, and negligible for
U54C. To evaluate the structural changes responsible for
the perturbed tyrosylation kinetics, we investigated the
solution structure of each mutated tRNA molecule.
Architectural perturbations in the mutant human
mt-tRNATyr structures
The three mutated mt-tRNATyr variants were probed under
identical conditions in experiments run in parallel with the
wild-type molecule. Comparisons reveal alterations in all
cleavage patterns as depicted in Figure 3.
For the U54C mutant, changes in nuclease probing
are faint and concern essentially residues 14–23 (D-loop),
57, 58 (T-loop), and G24 (D-stem) that all become less
accessible to S1 and T1 nucleases, compared to wild-type
transcript. The reduced accessibility of residues 53 and 54
is confirmed by the absence of Pb2+ cleavages at these
positions. Further, residue U63 (T-arm) is seen more
accessible to V1 in the mutated molecule. Despite these sub-
tle changes, both U54C and wild-type patterns are globally
similar (cf. Figs. 2A and 3A).
Second, mutant G15A and A22G exhibit similar nuclease
cleavage profiles that however differ from that of the wild-
type molecule. More precisely, both mutants show en-
hanced T2-cuts in the D-loop region (from residue 13–22)
as well as new S1-cuts in the anticodon stem-region (from
residue 13–44) not seen in the wild-type molecule. Further,
in mutant G15A, residues 48–50 are accessible to V1 as well
as nucleotide 15 that is more reactive to T2 nuclease.
Regarding mutant A22G, residues G13 and G24 show
enhanced cuts by T1. Finally, both mutants exhibit similar
Pb2+ cleavage patterns that differ from the wild-type mt-
tRNATyr at positions 9–12 and 16 for G15A transcript and
at positions 9 and 10 for A22G transcript.
Inspection of control lanes reveals significant differences
in the distribution of hydrolytic cleavages (Figs. 2A, 3A).
Whereas the wild-type and mutant U54C show almost no
hydrolytic cuts, mutant G15A and A22G present a larger
number. These cuts are of variable intensities and corre-
spond mainly to PyA sequences in connecting regions as,
for example, C25A26 and C48A49 (Fig. 3B). They reflect
the accessibility of tRNA backbone to water molecules and
especially the facilitated formation of cyclic phosphates due
to a greater flexibility of the molecule (Dock-Bregeon and
Moras 1987; Giege´ et al. 2001).
Altogether, nucleases, lead, and hydrolytic cuts point
toward an overall similar structural fold for both wild-type
and U54C transcripts that differ from that of the G15A and
A22G molecules. These latter are similar and present altered
conformations together with an enhanced structural plasticity.
Toward understanding the structural role of residues
G15, A22, and U54
Tyrosine identity determinants in human mt-tRNATyr (anti-
codon G34 U35 A36 and discriminator A73) are located
TABLE 1. Tyrosylation by human mt-TyrRS of wild-type and pathology-related mt-tRNATyr variants
mt-tRNATyr transcripts Gene mutation KM (mM) kcat (10
3sec1) kcat/KM (103s1mM1) La (x-fold)
Wild type 4.8 46 9.6 1
G15A C5877T 0.8 0.2 0.25 40
A22G T5874C 1.6 0.03 0.016 600
U54C A5843G 2.2 12 5.4 1.8
aL values correspond to losses of catalytic efficiency relative to wild-type human mt-tRNATyr.
Bonnefond et al.
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at the distal ends of the L-shaped tRNA (Bonnefond et al.
2005b). According to identity rules, specific aminoacylation
results from a productive interaction between the identity
nucleotides and the amino acids of the cognate synthetase
(for review, see Giege´ et al. 1998; Giege´ and Frugier 2003).
Given the proposed model, residues 15, 22, and 54 are not
thought to directly contact the synthetase (Fig. 1B). Thus,
mutations of these residues should not
affect tyrosylation properties of the cor-
responding transcripts unless their ter-
tiary structure is perturbed. This occurs
with the U54C mutant that presents a
probing pattern essentially similar to
that of wild type. In the case of the
G15A and A22G mutants, the losses in
tyrosylation efficiency reflect a struc-
tural alteration. In what follows, we
consider each mutation individually.
Residue U54 is conserved in the
majority of cytosolic tRNAs where it
interacts with A58 to give the proper
conformation to the T-loop (for review,
see Giege´ and Frugier 2003). In human
mt-tRNATyr, residue U54 cannot fulfill
this structural role due to the reduced
size of the T-loop. Further, the noncon-
servation of this residue in mt-tRNATyr
species does not support a structural
role of U54. Indeed, kinetic parameters
for tyrosylation are not affected by
the pathogenic mutation, confirming
that the replacement of U by C does
not perturb the overall structure of
human mt-tRNATyr. This agrees with a
globally unchanged sensitivity of this
tRNA to the structural probes. There-
fore, the efficient tyrosylation activity of
this mutant implies that the pathogenic
mutation affects essential interaction(s)
with other partner(s) of mt-tRNATyr.
Residue G15, conserved in almost all
mammalian mt-tRNATyr sequences, is
known to interact with C48 in the vari-
able region of canonical tRNAs (Giege´
and Frugier 2003). This tertiary interac-
tion can be maintained in mt-tRNATyr
(Fig. 1A) since C48 is present. In the
pathogenic mutant G15A, this pair is
likely disrupted, as shown by the en-
hanced reactivity of both residues A15
and C48 in the mutant compared to the
wild-type transcript. This disruption
probably triggers a structural destabili-
zation in both D-arms and anticodon
arms as shown by the increased number
of cuts in these regions that behave as single strands. This
perturbation explains the decreased tyrosylation ability
(40-fold) of the mutated transcript.
As found for class II tRNAs with large variable regions,
pairing between A22 and G13 probably also occurs in
human mt-tRNATyr. Substituting A22G leads either to a
larger and nonisosteric G13–G22 pair with only one H-bond
FIGURE 3. Structural analysis of mutants 15, 22, and 54. (A) Autoradiograms of 12%
denaturing gels of probing experiments performed on mt-tRNATyr G15A, A22G, and U54C
variants. The left and right panels correspond to Pb2+ and nuclease probing, respectively. For
annotations, see the legend of Figure 2A. The white triangles indicate the location of the
pathogenic mutation in each molecule. (B) Interpretation of the cleavages on schematic
cloverleaf folds. Nucleotides are represented by small dots (for the complete mt-tRNATyr se-
quence, see Fig. 2B) except the mutated residue shown explicitly for each variant. Nucleotides
showing strong increased or decreased cuts (compared to the wild-type mt-tRNATyr molecule)
are emphasized in gray. Strokes indicate positions of hydrolytic cuts. Bars at both 39- and
59-ends correspond to noninterpretable regions.
tRNA structure perturbations and pathologies
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(Leontis et al. 2002) or to a total disruption. This latter
hypothesis is favored, given the enhanced cuts observed for
residues G13, G22, and G24. Similar to mutant G15A, the
mutation triggers a structural change in the tRNA that
propagates in a zipper-like fashion from the D-stem toward
the anticodon stem, both seen more accessible to probes.
Thus, the strong loss in tyrosylation for mutant A22G is
due to a structural perturbation of the molecule and clearly
indicates a key role of residue A22 in the 3D architecture of
the mitochondrial tRNA, as is the case for mutation G15A.
Altogether, our data show that residue U54 does not con-
tribute to the long-range tertiary network of mt-tRNATyr
as opposed to nucleotides G15 and A22. Both residues,
located in the D-loop, probably stabilize the tRNA by
making tertiary interactions with residues located in the
variable region (C48) and in the D-loop (G13), respectively.
Final considerations
Only few studies relate to pathogenic mutations of mt-
tRNA genes taking place in single-stranded regions and
particularly in D- and T-loops. For example, mutation
A10044G in mt-tRNAGly gene changing A58 into G in the
T-loop weakens the interaction between D- and T-loops
and therefore interferes with the CCA adding enzyme
(Tomari et al. 2003). Further, mutation A4317G in mt-
tRNAIle gene induces an alternative T-stem structure
incompatible with aminoacylation (Kelley et al. 2001), a
possibility favored by the structural fragility of the mt-
tRNA (Kelley et al. 2000). In the case of mt-tRNATyr, a
direct implication of G15 and A22 in the tyrosylation
process is ruled out based on crystallographic knowledge of
the mt-TyrRS (Bonnefond et al. 2007b) and of T. thermo-
philus (Yaremchuk et al. 2002), Methanococcus jannaschii
(Kobayashi et al. 2003), and cytosolic Saccharomyces
cerevisiae (Tsunoda et al. 2007) tRNATyr/TyrRS complexes.
We show here that the aminoacylation deficiencies are due
to structural perturbations and correspond to the initial
impact of the mutations. Our study strengthens the fact
that local perturbations either in stem or loop regions
as well as chemical fragility of a mutated tRNA affect re-
cognition by tRNA-specific enzymes. Despite the absence of
crystallographic data, the combined result of structural
probing and tyrosylation assays supports the existence of
G13A22 and G15C48 tertiary interactions. The strong
conservation of residues G13, G15, A22 (> 90%), and
C48 (87%) in 150 mammalian mt-tRNATyr species further
supports this interpretation.
On the other hand, the pathogenic mutation U54C
(A5843G in the gene) affects neither aminoacylation nor
tRNA structure. Similarly, it has been reported that
mutation A55G in mt-tRNALys (A8344G in the gene) does
not prevent in vitro aminoacylation by mt-LysRS (Sissler
et al. 2004). Here, the deleterious effect of mutation U54C
has to be sought among the multiple steps of the tRNA life
cycle. Such knowledge is crucial to understand the patho-
genic effect triggered by the mutation.
MATERIAL AND METHODS
Materials
All mt-tRNATyr transcripts were produced in vitro using the
‘‘transzyme’’ method and purified as described in Fechter et al.
(1998). Briefly, the synthetic genes composed of overlapping
oligonucleotides contain a T7 RNA polymerase promoter fol-
lowed by a hammerhead ribozyme and tRNA sequences. A BstNI
site, coincidental with the 39-end of the tRNA sequence, allows
synthesis of tRNAs ending with the expected CCA-39-sequence.
After transcription, the hammerhead ribozyme self-cleaves and
liberates the tRNA. Before use in functional and structural assays,
tRNA transcripts were renatured by heating at 60°C for 90 sec in
water followed by a slow cooling to room temperature.
The C-terminal His-tagged human mt-TyrRS was cloned,
expressed, and purified as described elsewhere (Bonnefond et al.
2005a).
Aminoacylation assays
Tyrosylation assays were performed at 37°C in 50 mM HEPES-
NaOH (pH 7.6) buffer containing 25 mM KCl, 12 mM MgCl2,
2.5 mM ATP, 0.2 mg/mL bovine serum albumin, 1 mM spermine,
and 10 mM L-[3H]-tyrosine at 49 Ci/mmol (Sohm et al. 2003).
Apparent kinetic parameters were determined from Lineweaver-
Burk plots in the presence of mt-TyrRS (diluted in 100 mMHEPES-
NaOH pH 7.4, 1 mM DTT, 5 mg/mL bovine serum albumin, and
10% glycerol) and transcript concentrations ranging from 0.2 to
2 mM. Depending on the degree of impairment of tRNA activity,
mt-TyrRS concentrations varying from 75 nM to 1.5 mM were
used. Experimental errors on kcat and KM varied at most by 20%.
Numerical values are averages of at least two independent
experiments.
Structural mapping procedures
Structural mapping of transcripts was done using chemical and
enzymatic probes that preferentially cut single-stranded (Pb2+ and
T1, S1, T2 nucleases) and double-stranded or highly structured
domains (RNase V1). Labeling the 59-end of mt-tRNATyr transcripts
was performed as described (Silberklang et al. 1977). Digestions of
tRNAs with nucleases was for 10 min at 25°C in buffer T (25 mM
KCl, 10 mM MgCl2, and 50 mM HEPES-NaOH pH 7.5). For
digestion with S1 nuclease, 1 mM ZnCl2 was added. Reaction
mixtures (10 mL) contained 100,000 Cerenkov cpm of transcript
supplemented with 20 pmol of unlabeled tRNA and either 9 3
104 U RNase V1, 4.7 U nuclease S1, 0.18 U RNase T1, or 3.5 3
102 U RNase T2. Reactions were stopped on ice and by addition
of 20 mL 0.6 M NaOAc, 4 mM EDTA, and 0.1 mg/mL total tRNA,
followed by phenol extraction and ethanol precipitation of the
tRNA. A freshly prepared Pb(Oac)2 solution in H2O was used at 3
and 10 mM final concentrations. Samples (10 mL) were incubated
for 6 min at 25°C. Reactions were stopped by cooling on ice,
adding EDTA to a final concentration of 33 mM and ethanol
precipitated. Controls without probes were run in parallel on each
gel.
Bonnefond et al.
646 RNA, Vol. 14, No. 4
JOBNAME: RNA 14#4 2008 PAGE: 6 OUTPUT: Saturday March 8 14:53:25 2008
csh/RNA/152278/rna9381
For assignment of cleavage positions, alkaline degradations
were performed by incubation of labeled transcripts for 4 min
at 80°C in 50 mM NaHCO3 pH 9.0. Guanine ladders were
generated by RNase T1 digestion under denaturing conditions
(Peattie and Gilbert 1980). All experiments were performed and
run in parallel with the same nuclease and Pb2+ dilutions.
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